Biology Reference
In-Depth Information
262. Greenstock CL. Radiation and aging: free radical damage, bio-
logical response and possible antioxidant
271. Robak T, G´ ra-Tybor J. Cladribine combined with mitoxantrone
in the treatment of blastic phase of chronic myeloid leukemia.
Neoplasma
2001;48:203
intervention.
Med
7.
272. Stachelek GC, Dalal S, Donigan KA, Campisi Hegan D,
Sweasy JB, Glazer PM. Potentiation of temozolomide cytotoxicity
by inhibition of DNA polymerase beta is accentuated by BRCA2
mutation.
Cancer Res
2010;70:409
82.
263. Dextraze ME, Gantchev T, Girouard S, Hunting D. DNA inter-
strand cross-links induced by ionizing radiation: an unsung
lesion.
Mutat Res
2010;704:101
Hypotheses
1993;41:473
e
e
7.
264. Gr´goire V, Beauduin M, Bruniaux M, et al. Radiosensitization of
mouse sarcoma cells by fludarabine (F-ara-A) or gemcitabine
(dFdC), two nucleoside analogues, is not mediated by an
increased induction or a repair inhibition of DNA double-strand
breaks as measured by pulsed-field gel electrophoresis.
Int J
Radiat Biol
1998;73:511
e
17.
273. Kozoni V, Tsioulias G, Shiff S, Rigas B. The effect of lithocholic
acid on proliferation and apoptosis during the early stages of
colon carcinogenesis: differential effect on apoptosis in the pres-
ence of a colon carcinogen.
Carcinogenesis
2000;21:999
e
1005.
274. McCaffrey R, Bell R, Lillquist A, Wright G, Baril E, Minowada J.
Selective killing of leukemia cells by inhibition of TdT.
Haematol
Blood Transfus
1983;28:24
e
20.
265. Zhu Y, Hu J, Hu Y, Liu W. Targeting DNA repair pathways:
a novel approach to reduce cancer therapeutic resistance.
Cancer
Treat Rev
2009;35:590
e
7.
275. Spigelman Z, Duff R, Beardsley GP, et al. 2',3'-Dideoxyadenosine
is selectively toxic for TdT-positive cells.
Blood
1988;71:1601
e
6.
266. Laurent D, Pradier O, Schmidberger H, Rave-Fr¨nk M,
Frankenberg D, Hess CF. Radiation rendered more cytotoxic by
fludarabine monophosphate in a human oropharynx carcinoma
cell-line than in fetal lung fibroblasts.
J Cancer Res Clin Oncol
1998;124:485
e
8.
276. Kodama EN, McCaffrey RP, Yusa K, Mitsuya H. Antileukemic
activity and mechanism of action of cordycepin against terminal
deoxynucleotidyl
e
transferase-positive (TdT
þ
)
leukemic cells.
81.
277. Strauss BS. The “A” rule revisited: polymerases as determinants
of mutational specificity.
DNA Repair (Amst)
2002;28:125
Biochem Pharmacol
2000;59:273
e
92.
267. Mackall CL. T-cell immunodeficiency following cytotoxic anti-
neoplastic therapy: a review.
Oncologist
1999;4:370
e
35.
278. Zhang X, Lee I, Berdis AJ. A potential chemotherapeutic strategy
for the selective inhibition of promutagenic DNA synthesis by
nonnatural nucleotides.
Biochemistry
2005;44:13111
e
8.
268. Juliusson G, Lenkei R, Liliemark J. Flow cytometry of blood and
bone marrow cells from patients with hairy cell leukemia:
phenotype of hairy cells and lymphocyte subsets after treatment
with 2-chlorodeoxyadenosine.
Blood
1994;83:3672
e
21.
279. Vineyard D, Zhang X, Donnelly A, Lee I, Berdis AJ. Optimization
of non-natural nucleotides for selective incorporation opposite
damaged DNA.
Org Biomol Chem
2007;5:3623
e
81.
269. Juliusson G. Complications in the treatment of CLL with purine
analogues.
Hematol Cell Ther
1997;39:S41
e
30.
280. Zhang X, Donnelly A, Lee I, Berdis AJ. Rational attempts to opti-
mize non-natural nucleotides for selective incorporation opposite
an abasic site.
Biochemistry
2006;45:13293
e
4.
270. Ravandi F, O'Brien S. Infections associated with purine analogs
and monoclonal antibodies.
Blood Rev
2005;19:253
e
73.
303.
e
e
